A framework for planning and critiquing medication compliance and persistence research using prospective study designs

Clinical Therapeutics

Volumn 31, Issue 2, 2009, Pages 421-435

  Gwadry Sridhar, Femida H ^a   Manias, Elizabeth ^b   Zhang, Ying ^c   Roy, Anuja ^d   Yu Isenberg, Kristina ^e   Hughes, Dyfrig A ^f   Nichol, Michael B ^g  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b Faculty of Medicine Dentistry and Health Sciences   (Australia)

^c ACADIA UNIVERSITY   (Canada)

^d Walgreens Health Services   (United States)

^e Regional Outcomes Research   (United States)

^f BANGOR UNIVERSITY   (United Kingdom)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

compliance; persistence; prospective design

Indexed keywords

ARTICLE; CINAHL; CONSUMER; DATA ANALYSIS; DESCRIPTIVE RESEARCH; EMBASE; HEALTH CARE PERSONNEL; INFORMATION RETRIEVAL; LONGITUDINAL STUDY; MEDLINE; METHODOLOGY; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PATIENT MONITORING; PROSPECTIVE STUDY; QUALITY CONTROL; QUASI EXPERIMENTAL STUDY; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

CLINICAL TRIALS AS TOPIC; HUMANS; MEDICATION ADHERENCE; PHARMACEUTICAL PREPARATIONS; PROSPECTIVE STUDIES; RESEARCH; RESEARCH DESIGN; TREATMENT OUTCOME; VALIDATION STUDIES AS TOPIC;

EID: 62549093536     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.02.021     Document Type: Article

References (102)

1. Guyatt G.H., Haynes R.B., Jaeschke R.Z., et al., for the Evidence-Based Medicine Working Group. Users' Guides to the Medical Literature: XXV. Evidence-based medicine: Principles for applying the Users' Guides to patient care. JAMA 284 (2000) 1290-1296
2. Guyatt G., Rennie D., Meade M., and Cook D. Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. 2nd ed (2008), McGraw-Hill, New York, NY
3. Friedman L.M., Furberg C.D., and DeMets D.L. Fundamentals of Clinical Trials. 2nd ed (1985), PSG Publishing, Littleton, MA
4. Peterson A.M., Nau D.P., Cramer J.A., et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 10 (2007) 3-12
5. National Cancer Institute. Theory at a Glance: A Guide for Health Promotion Practice [National Cancer Institute Web site].
6. (August 10, 2008). http://www.cancer.gov/aboutnci/oc/theoryat-a-glance Accessed
7. Glanz K., Rimer B.K., and Lewis F.M. Health Behavior and Health Education: Theory, Research, and Practice. 3rd ed (2002), Jossey-Bass, San Francisco, CA
8. Adams J., and Scott J. Predicting medication adherence in severe mental disorders. Acta Psychiatr Scand 101 (2000) 119-124
9. Scott J. Using Health Belief Models to understand the efficacy-effectiveness gap for mood stabilizer treatments. Neuropsychobiology 46 Suppl 1 (2002) 13-15
10. Steele R.G., Anderson B., Rindel B., et al. Adherence to antiretroviral therapy among HIV-positive children: Examination of the role of caregiver health beliefs. AIDS Care 13 (2001) 617-629
11. Ogden J. Health Psychology: A Textbook. 2nd ed (2000), Open University Press, Buckingham, UK
12. Edwards W. The theory of decision making. Psychol Bull 51 (1954) 380-417
13. Whitehead D. A social cognitive model for health education/health promotion practice. J Adv Nurs 36 (2001) 417-425
14. Prochaska J.O., DiClemente C.C., and Norcross J.C. In search of how people change. Applications to addictive behaviors. Am Psychol 47 (1992) 1102-1114
15. Family Health International (FHI). Behavior Change-A Summary of Four Major theories.
16. (November 29, 2008). http://www.fhi.org/nr/rdonlyres/ei26vbslpsidmahhxc332vwo3g233xsgw22er3vo fgvrfjvubwyzclvgjcbdgexyzl3msu4mn6xv5j/bccsummaryfourmajortheories.pdf Accessed
17. Brassington G.S., Atienza A.A., Perczek R.E., et al. Intervention-related cognitive versus social mediators of exercise adherence in the elderly. Am J Prev Med 23 Suppl 2 (2002) 80-86
18. Conner M., and Norman P. A social cognitive approach. In: Conner M., and Norman P. (Eds). Predicting Health Behaviour (2005), Open University Press, New York, NY 170-222
19. Bandura A. Self-Efficacy: The Exercise of Control (1997), Freeman, New York, NY
20. Cramer J.A., Roy A., Burrell A., et al. Medication compliance and persistence: Terminology and definitions. Value Health 11 (2008) 44-47
21. Montague T. Merck Frosst Pharmaceutical Report for the British Pharmaceutical Society on Medication Compliance (1997), Merck Frosst Pharmaceutical, Montreal, Quebec, Canada
22. Haynes R.B. A critical review of the "determinants" of patient compliance with therapeutic regimens. In: Sackett D.L., and Haynes R.B. (Eds). Compliance with Therapeutic Regimens (1976), Johns Hopkins University Press, Baltimore, MD 11-22
23. In: Burke L.E., and Ockene I.S. (Eds). Compliance in Healthcare and Research (2001), Futura Publishing Co, Inc, Armonk, NY
24. Vermeire E., Hearnshaw H., Van Royen P., and Denekens J. Patient adherence to treatment: Three decades of research. A comprehensive review. J Clin Pharm Ther 26 (2001) 331-342
25. Lash S., and Harding J. "Abandoned prescriptions": A quantitative assessment of their cause. J Managed Care Pharm 1 (1995) 193-199
26. West J.A., Miller N.H., Parker K.M., et al. A comprehensive management system for heart failure improves clinical outcomes and reduces medical resource utilization. Am J Cardiol 79 (1997) 58-63
27. DiMatteo M.R., Lepper H.S., and Croghan T.W. Depression is a risk factor for noncompliance with medical treat ment: Meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 160 (2000) 2101-2107
28. McDonald H.P., Garg A.X., and Haynes R.B. Interventions to enhance patient adherence to medication pre scriptions: Scientific review [published correction appears in JAMA. 2003;289:3242]. JAMA 288 (2002) 2868-2879
29. DiMatteo M.R., Giordani P.J., Lepper H.S., and Croghan T.W. Patient adherence and medical treatment out comes: A meta-analysis. Med Care 40 (2002) 794-811
30. McDermott M.M., Schmitt B., and Wallner E. Impact of medication nonadherence on coronary heart disease outcomes. A critical review. Arch Intern Med 157 (1997) 1921-1929
31. Special Report: Interventions to improve patient adherence with medications for chronic cardiovascular disorders. TEC Bull (Online) 20 (2003) 30-32
32. Simpson S.H., Eurich D.T., Majumdar S.R., et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 333 (2006) 15
33. Elliott R.A., Barber N., and Horne R. Cost-effectiveness of adherence-enhancing interventions: A quality assessment of the evidence. Ann Pharmacother 39 (2005) 508-515
34. The Evidence-Based Medicine Working Group. In: Guyatt G., and Rennie D. (Eds). Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice (2002), AMA Press, Chicago, IL
35. Volume C.I., Farris K.B., Kassam R., et al. Pharmaceutical care research and education project: Patient outcomes. J Am Pharm Assoc (Wash) 41 (2001) 411-420
36. Vrijens B., Belmans A., Matthys K., et al. Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Pharmacoepidemiol Drug Saf 15 (2006) 115-121
37. Cramer J.A. Consequences of intermittent treatment for hypertension: The case for medication compliance and persistence. Am J Manag Care 4 (1998) 1563-1568
38. Gwadry-Sridhar F.H., Arnold J.M., Zhang Y., et al. Pilot study to determine the impact of a multidisciplinary educational intervention in patients hospitalized with heart failure. Am Heart J 150 (2005) 982
39. CONSORT Group. The CONSORT Statement.
40. (November 29, 2008). http://www.consortstatement.org/ Accessed
41. Haynes R.B., Sackett D.L., Guyatt G.H., and Tugwell P. Clinical Epidemiology: How to Do Clinical Practice Research. 3rd ed (2006), Lippincott Williams & Wilkins, Philadelphia, PA
42. Diggle P.J., Liang K.Y., and Zeger S.L. Analysis of Longitudinal Data. 2nd ed (2002), Oxford University Press, Oxford, UK
43. Moher D., Schulz K.F., Altman D.G., and for the CONSORT GROUP (Consolidated Standards of Reporting Trials). The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 134 (2001) 657-662
44. Altman D.G., Schulz K.F., Moher D., et al., for the CONSORT GROUP (Consolidated Standards of Reporting Trials). The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. Ann Intern Med 134 (2001) 663-694
45. Norman G.R., and Streiner D.L. Biostatistics: The Bare Essentials. 3rd ed (2008), Decker, Hamilton, Ontario, Canada
46. Haynes R.B., Yao X., Degani A., et al. Interventions to enhance medication adherence. Cochrane Database Syst Rev 4 (2005) CD000011. Update in: Cochrane Database System Rev. 2008;CD000011
47. Jadad A.R. Randomised Controlled Trials: A User's Guide (1998), BMJ Books, London, UK
48. Gehlbach S.H. Interpreting the Medical Literature (2006), McGrawHill, New York, NY
49. Qureshi N.N., Hatcher J., Chaturvedi N., Jafar T.H., and for the Hypertension Research Group. Effect of general practitioner education on adherence to antihypertensive drugs: Cluster randomised controlled trial. BMJ 335 (2007) 1030
50. Donner A., and Klar N. Design and Analysis of Cluster Randomization Trials in Health Research (2000), Arnold, London, UK
51. Mayer D. Essential Evidence-Based Medicine (2004), Cambridge University Press, New York, NY
52. Donner A., and Klar N. Pitfalls ofand controversies in cluster randomization trials. Am J Public Health 94 (2004) 416-422
53. Grant R.W., Devita N.G., Singer D.E., and Meigs J.B. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care 26 (2003) 1408-1412
54. Smeeth L., and Ng E.S. Intraclass correlation coefficients for cluster randomized trials in primary care: Data from the MRC Trial of the Assessment and Management of Older People in the Community. Control Clin Trials 23 (2002) 409-421
55. Hedges L.V., and Hedberg E.C. Intraclass correlation values for planning group randomized trials in education. Educ Eval Policy Anal 29 (2007) 60-87
56. Campbell D.T., and Stanley J.C. Experimental and Quasi-Experimental Designs for Research (1966), R. McNally, Chicago, IL
57. Sit J.W., Yip V.Y., Ko S.K., et al. A quasiexperimental study on a community-based stroke prevention programme for clients with minor stroke. J Clin Nurs 16 (2007) 272-281
58. Gallegos E.C., Ovalle-Berúmen F., and Gomez-Meza M.V. Metabolic control of adults with type 2 diabetes mellitus through education and counseling. J Nurs Scholarsh 38 (2006) 344-351
59. Gilbert A., Owen N., Sansom L., and Innes J.M. High level of medication compliance and blood pressure control among hypertensive patients attending community pharmacies. J Soc Admin Pharm 7 (1990) 78-83
60. Widmer R.B., Cadoret R.J., and Troughton E. Compliance characteristics of 291 hypertensive patients from a rural midwest area. J Fam Pract 17 (1983) 619-625
61. Mann C.J. Observational research methods. Research design II: Cohort, cross sectional, and case-control studies. Emerg Med J 20 (2003) 54-60
62. Kottke T.E., Solbert L., and Brekke M. Organizational approaches to improve compliance. In: Burke L.E., and Okene I.S. (Eds). Compliance in Healthcare and Research (2001), Futura Publishing Co, Armonk, NY 81-90
63. Osterberg L., and Blaschke T. Adherence to medication. N Engl J Med 353 (2005) 487-497
64. Streiner D.L., and Norman G.R. Health Measurement Scales: A Practical Guide to Their Development and Use. 2nd ed (1995), Oxford University Press, Oxford, UK
65. Haynes R.B., Ackloo E., Sahota N., et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev (2008) CD000011
66. Kruse W. Patient compliance with drug treatment-new perspectives on an old problem. Clin Investig 70 (1992) 163-166
67. Steiner J.F., and Prochazka A.V. The assessment of refill compliance using pharmacy records: Methods, validity, and applications. J Clin Epidemiol 150 (1997) 105-116
68. Cramer J.A. Relationship between medication compliance and medical outcomes. Am J Health Syst Pharm 52 Suppl 3 (1995) S27-S29
69. Aardex. The Measurement.
70. (February 9, 2009). http://www.aardexgroup.com/aardex_index.php?group=aardex Accessed
71. Myers L.B., and Midence K. Methodological and conceptual issues in adherence. In: Myers L.B., and Midence K. (Eds). Adherence to Treatment in Medical Conditions (1998), Harwood Academic, Amsterdam, The Netherlands 1-24
72. Diaz E., Levine H.B., Sullivan M.C., et al. Use of the Medication Event Monitoring System to estimate medication compliance in patients with schizophrenia. J Psychiatry Neurosci 26 (2001) 325-329
73. Vrijens B., Vincze G., Kristanto P., et al. Adherence to prescribed antihypertensive drug treatments: Longitudinal study of electronically compiled dosing histories. BMJ 336 (2008) 1114-1117
74. Cramer J.A., Ouellette V.L., and Mattson R.H. The effect of microelectronic observation on compliance. Epilepsia 31 (1990) 617-618 Abstract
75. Waterhouse D.M., Calzone K.A., Mele C., and Brenner D.E. Adherence to oral tamoxifen: A comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 11 (1993) 1189-1197
76. Matsui D., Hermann C., Klein J., et al. Critical comparison of novel and existing methods of compliance assessment during a clinical trial of an oral iron chelator. J Clin Pharmacol 34 (1994) 944-949
77. Burnier M., Schneider M.P., Chioléro A., et al. Electronic compliance monitoring in resistant hypertension: The basis for rational therapeutic decisions. J Hypertens 19 (2001) 335-341
78. Urquhart J. The odds of the three nons when an aptly prescribed medicine isn't working: Non-compliance, non-absorption, non-response. Br J Clin Pharmacol 54 (2002) 212-220
79. In: Burke L.E., and Ockene I.S. (Eds). Compliance in Healthcare and Research (2001), Futura Publishing Company, Armonk, NY
80. Rothman K.J., Greenland S., and Lash T.L. Modern Epidemiology. 3rd ed (2008), Lippincott Williams & Wilkins, Philadelphia, PA
81. Cabilio P., and Masaro J. Biostatistics Part II Data Analysis and Methods: A Workbook Approach (2005), Dept of Mathematics & Statistics, Acadia University, Wolfville, Nova Scotia, Canada
82. Hirsch R.P., and Riegelman R.K. Statistical First Aid: Interpretation of Health Research Data (1992), Blackwell Scientific Publications, Boston, MA
83. Silverman B.W. Density Estimation for Statistics and Data Analysis (1998), Chapman & Hall/CRC, Boca Raton, FL
84. Grubisic M. Metric Development for Medication Compliance Using a Distribution Approach [master's thesis] (2006), Acadia University, Wolfville, Nova Scotia, Canada
85. Statistics Department of the University of Auckland. The R Project for Statistical Computing 2007 [R Project Web site].
86. (November 29, 2008). http://www.r-project.org/ Accessed
87. Gibbons J.D., and Chakraborti S. Nonparametric Statistical Inference. 3rd ed (1992), M Dekker, New York, NY
88. Yu A.P., Yu Y.F., Nichol M.B., and Gwadry-Sridhar F. Delay in filling the initial prescription for a statin: A potential early indicator of medication nonpersistence. Clin Ther 30 (2008) 761-774
89. Zeger S.L., Liang K.Y., and Albert P.S. Models for longitudinal data: A generalized estimating equation approach [published correction appears in Biometrics. 1989;45:347]. Biometrics 44 (1988) 1049-1060
90. Smith D.M., and Diggle P.J. Compliance in an anti-hypertension trial: A latent process model for binary lon gitudinal data. Stat Med 17 (1998) 357-370
91. Girard P., Blaschke T.F., Kastrissios H., and Sheiner L.B. A Markov mixed effect regression model for drug compliance. Stat Med 17 (1998) 2313-2333
92. Collett D. Modelling Survival Data in Medical Research. 1st ed (1994), Chapman & Hall, London, UK; New York, NY
93. Mielke Jr. P.W., and Berry K.J. Permutation Methods: A Distance Function Approach (2001), Springer, New York, NY
94. Hughes D. When drugs don't work: Economic assessment of enhancing compliance with interventions supported by electronic monitoring devices. PharmacoEconomics 25 (2007) 621-635
95. Ramsey S., Willke R., Briggs A., et al. Good research practices for cost-effectiveness analysis alongside clinical trials: The ISPOR RCT-CEA Task Force report. Value Health 8 (2005) 521-533
96. Hughes D., Cowell W., Koncz T., Cramer J., and for the International Society for Pharmacoeconomics & Out comes Research Economics of Medication Compliance Working Group. Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. Value Health 10 (2007) 498-509
97. Rabin R., and de Charro F. EQ-5D: A measure of health status from the EuroQol Group. Ann Med 33 (2001) 337-343
98. The EuroQol Group. What is EQ5D? EQ-5D is standardised instrument for use as a measure of health outcome [EuroQol Group Web site].
99. (November 29, 2008). http://www.eurogol.org/ Accessed
100. In: Kind P., Brooks R., and Rabin R. (Eds). EQ-5D Concepts and Methods: A Developmental History (2005), Springer, Dordecht, The Netherlands
101. ®): Concepts, measurement properties and applications. Health Qual Life Outcomes 1 (2008-November 29, 2008) 1-54. http://www.hglo.com/content/1/1/54 Accessed
102. Sokol M.C., McGuigan K.A., Verbrugge R.R., and Epstein R.S. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 43 (2005) 521-530